🇺🇸 FDA
Patent

US 10398661

Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers

granted A61KA61K2039/505A61K31/19

Quick answer

US patent 10398661 (Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers) held by The Board of Regents of the University of Texas System expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2039/505, A61K31/19, A61K45/06, A61P